Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alterity Therapeutics ( (AU:ATH) ) has issued an announcement.
Alterity Therapeutics reported that it successfully completed its Phase 2 clinical program for lead candidate ATH434 in multiple system atrophy during 2025, with data showing the drug was safe, well-tolerated, and associated with slowing disease progression across several clinical endpoints, including functional measures, mobility, and orthostatic hypotension. Building on these results, the company is now preparing for an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize a Phase 3 trial design, scaling its clinical, manufacturing, and regulatory infrastructure and deepening engagement with key neurologists, while also strengthening its board and leadership team to support potential late-stage development and future commercialization.
The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Its lead asset, ATH434, targets multiple system atrophy (MSA), a severe and progressive disorder with no approved disease-modifying therapies, positioning the company within a high unmet-need segment of the neurology market, including a potential MSA market opportunity estimated at $2.4 billion.
Average Trading Volume: 16,694,672
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$87M
See more insights into ATH stock on TipRanks’ Stock Analysis page.